The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway

Seminars in Cell and Developmental Biology

Volumn 23, Issue 7, 2012, Pages 785-793

  Hong, Wanjin ^a,b   Guan, Kun Liang ^c  

^a XIAMEN UNIVERSITY   (China)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Hippo; Transcription co activator; YAP; Yki

Indexed keywords

PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TAZ; TRANSCRIPTION FACTOR YAP1; TRANSCRIPTION FACTOR YKI; UNCLASSIFIED DRUG;

CARCINOGENESIS; DROSOPHILA; HIPPO SIGNALING PATHWAY; MAMMAL; MOLECULAR BIOLOGY; NONHUMAN; PHYSIOLOGY; PROTEIN ANALYSIS; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 84866621687     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2012.05.004     Document Type: Review

References (83)

1. Zhao B., Li L., Lei Q., Guan K.L. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes and Development 2010, 24:862-874.
2. Pan D. The hippo signaling pathway in development and cancer. Developmental Cell 2010, 19:491-505.
3. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 1994, 9:2145-2152.
4. Sudol M., Bork P., Einbond A., Kastury K., Druck T., Negrini M., et al. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. Journal of Biological Chemistry 1995, 270:14733-14741.
5. Bork P., Sudol M. The WW domain: a signalling site in dystrophin. Trends in Biochemical Sciences 1994, 19:531-533.
6. Chen H.I., Sudol M. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:7819-7823.
7. Macias M.J., Hyvonen M., Baraldi E., Schultz J., Sudol M., Saraste M., et al. Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Nature 1996, 382:646-649.
8. Kanai F., Marignani P.A., Sarbassova D., Yagi R., Hall R.A., Donowitz M., et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO Journal 2000, 19:6778-6791.
9. Huang J., Wu S., Barrera J., Matthews K., Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 2005, 122:421-434.
10. Morin-Kensicki E.M., Boone B.N., Howell M., Stonebraker J.R., Teed J., Alb J.G., et al. Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65. Molecular and Cellular Biology 2006, 26:77-87.
11. Hossain Z., Ali S.M., Ko H.L., Xu J., Ng C.P., Guo K., et al. Glomerulocystic kidney disease in mice with a targeted inactivation of Wwtr1. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:1631-1636.
12. Tian Y., Kolb R., Hong J.H., Carroll J., Li D., You J., et al. TAZ promotes PC2 degradation through a SCFbeta-Trcp E3 ligase complex. Molecular and Cellular Biology 2007, 27:6383-6395.
13. Makita R., Uchijima Y., Nishiyama K., Amano T., Chen Q., Takeuchi T., et al. Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. American Journal of Physiology. Renal Physiology 2008, 294:F542-F553.
14. Kang H.S., Beak J.Y., Kim Y.S., Herbert R., Jetten A.M. Glis3 is associated with primary cilia and Wwtr1/TAZ and implicated in polycystic kidney disease. Molecular and Cellular Biology 2009, 29:2556-2569.
15. Yagi R., Chen L.F., Shigesada K., Murakami Y., Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO Journal 1999, 18:2551-2562.
16. Vassilev A., Kaneko K.J., Shu H., Zhao Y., DePamphilis M.L. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes and Development 2001, 15:1229-1241.
17. Xu T., Wang W., Zhang S., Stewart R.A., Yu W. Identifying tumor suppressors in genetic mosaics: the Drosophila Lats gene encodes a putative protein kinase. Development 1995, 121:1053-1063.
18. Justice R.W., Zilian O., Woods D.F., Noll M., Bryant P.J. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes and Development 1995, 9:534-546.
19. Harvey K.F., Pfleger C.M., Hariharan I.K. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 2003, 114:457-467.
20. Wu S., Huang J., Dong J., Pan D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003, 114:445-456.
21. Tapon N., Harvey K.F., Bell D.W., Wahrer D.C., Schiripo T.A., Haber D.A., et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002, 110:467-478.
22. Lai Z.C., Wei X., Shimizu T., Ramos E., Rohrbaugh M., Nikolaidis N., et al. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 2005, 120:675-685.
23. Zhao B., Wei X., Li W., Udan R.S., Yang Q., Kim J., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes and Development 2007, 21:2747-2761.
24. Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
25. Camargo F.D., Gokhale S., Johnnidis J.B., Fu D., Bell G.W., Jaenisch R., et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Current Biology 2007, 17:2054-2060.
26. Zeng Q., Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008, 13:188-192.
27. Basu S., Totty N.F., Irwin M.S., Sudol M., Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Molecular Cell 2003, 11:11-23.
28. Hong J.H., Hwang E.S., McManus M.T., Amsterdam A., Tian Y., Kalmukova R., et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309:1074-1078.
29. Chan S.W., Lim C.J., Guo K., Ng C.P., Lee I., Hunziker W., et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Research 2008, 68:2592-2598.
30. Lei Q.Y., Zhang H., Zhao B., Zha Z.Y., Bai F., Pei X.H., et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Molecular and Cellular Biology 2008, 28:2426-2436.
31. Oh H., Irvine K.D. In vivo analysis of Yorkie phosphorylation sites. Oncogene 2009, 28:1916-1927.
32. Zhao B., Li L., Tumaneng K., Wang C.Y., Guan K.L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes and Development 2010, 24:72-85.
33. Liu C.Y., Zha Z.Y., Zhou X., Zhang H., Huang W., Zhao D., et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. Journal of Biological Chemistry 2010, 285:37159-37169.
34. Wrighton K.H. Mechanotransduction: YAP and TAZ feel the force. Nature Reviews Molecular Cell Biology 2011, 12:404.
35. Fernandez B.G., Gaspar P., Bras-Pereira C., Jezowska B., Rebelo S.R., Janody F. Actin-capping protein and the Hippo pathway regulate F-actin and tissue growth in Drosophila. Development 2011, 138:2337-2346.
36. Sansores-Garcia L., Bossuyt W., Wada K., Yonemura S., Tao C., Sasaki H., et al. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO Journal 2011, 30:2325-2335.
37. Wada K., Itoga K., Okano T., Yonemura S., Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138:3907-3914.
38. Zhao B., Li L., Wang L., Wang C.Y., Yu J., Guan K.L. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes and Development 2012, 26:54-68.
39. Xiao J.H., Davidson I., Matthes H., Garnier J.M., Chambon P. Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1. Cell 1991, 65:551-568.
40. Ishiji T., Lace M.J., Parkkinen S., Anderson R.D., Haugen T.H., Cripe T.P., et al. Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO Journal 1992, 11:2271-2281.
41. Campbell S., Inamdar M., Rodrigues V., Raghavan V., Palazzolo M., Chovnick A. The scalloped gene encodes a novel, evolutionarily conserved transcription factor required for sensory organ differentiation in Drosophila. Genes and Development 1992, 6:367-379.
42. Anbanandam A., Albarado D.C., Nguyen C.T., Halder G., Gao X., Veeraraghavan S. Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:17225-17230.
43. Magico A.C., Bell J.B. Identification of a classical bipartite nuclear localization signal in the Drosophila TEA/ATTS protein scalloped. PLoS One 2011, 6:e21431.
44. Zhao B., Ye X., Yu J., Li L., Li W., Li S., et al. TEAD mediates YAP-dependent gene induction and growth control. Genes and Development 2008, 22:1962-1971.
45. Wu S., Liu Y., Zheng Y., Dong J., Pan D. The TEAD/TEF family protein scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Developmental Cell 2008, 14:388-398.
46. Zhang L., Ren F., Zhang Q., Chen Y., Wang B., Jiang J. The TEAD/TEF family of transcription factor scalloped mediates Hippo signaling in organ size control. Developmental Cell 2008, 14:377-387.
47. Chan S.W., Lim C.J., Loo L.S., Chong Y.F., Huang C., Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. Journal of Biological Chemistry 2009, 284:14347-14358.
48. Zhang H., Liu C.Y., Zha Z.Y., Zhao B., Yao J., Zhao S., et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. The Journal of Biological Chemistry 2009, 284:13355-13362.
49. Chen L., Chan S.W., Zhang X., Walsh M., Lim C.J., Hong W., et al. Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes and Development 2010, 24:290-300.
50. Li Z., Zhao B., Wang P., Chen F., Dong Z., Yang H., et al. Structural insights into the YAP and TEAD complex. Genes and Development 2010, 24:235-240.
51. Fossdal R., Jonasson F., Kristjansdottir G.T., Kong A., Stefansson H., Gosh S., et al. A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration). Human Molecular Genetics 2004, 13:975-981.
52. Chen H.I., Einbond A., Kwak S.J., Linn H., Koepf E., Peterson S., et al. Characterization of the WW domain of human Yes-associated protein and its polyproline-containing ligands. Journal of Biological Chemistry 1997, 272:17070-17077.
53. Chan S.W., Lim C.J., Huang C., Chong Y.F., Gunaratne H.J., Hogue K.A., et al. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ. Oncogene 2011, 30:600-610.
54. Zhang X., Milton C.C., Poon C.L., Hong W., Harvey K.F. Wbp2 cooperates with Yorkie to drive tissue growth downstream of the Salvador-Warts-Hippo pathway. Cell Death and Differentiation 2011, 18:1346-1355.
55. Lim S.K., Orhant-Prioux M., Toy W., Tan K.Y., Lim Y.P. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor alpha function in breast cancer via the Wnt pathway. FASEB Journal 2011, 25:3004-3018.
56. Zhao B., Li L., Lu Q., Wang L.H., Liu C.Y., Lei Q., et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes and Development 2011, 25:51-63.
57. Chan S.W., Lim C.J., Chong Y.F., Pobbati A.V., Huang C., Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. Journal of Biological Chemistry 2011, 286:7018-7026.
58. Wang W., Huang J., Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. Journal of Biological Chemistry 2011, 286:4364-4370.
59. Wells C.D., Fawcett J.P., Traweger A., Yamanaka Y., Goudreault M., Elder K., et al. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 2006, 125:535-548.
60. Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., et al. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011, 144:782-795.
61. Chan S.W., Lim C.J., Chen L., Chong Y.F., Huang C., Song H., et al. The Hippo pathway in biological control and cancer development. Journal of Cellular Physiology 2011, 226:928-939.
62. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.
63. Baldwin C., Garnis C., Zhang L., Rosin M.P., Lam W.L. Multiple microalterations detected at high frequency in oral cancer. Cancer Research 2005, 65:7561-7567.
64. Fernandez L., Northcott P.A., Dalton J., Fraga C., Ellison D., Angers S., et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes and Development 2009, 23:2729-2741.
65. Modena P., Lualdi E., Facchinetti F., Veltman J., Reid J.F., Minardi S., et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. Journal of Clinical Oncology 2006, 24:5223-5233.
66. Snijders A.M., Schmidt B.L., Fridlyand J., Dekker N., Pinkel D., Jordan R.C., et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene 2005, 24:4232-4242.
67. Xu M.Z., Yao T.J., Lee N.P., Ng I.O., Chan Y.T., Zender L., et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009, 115:4576-4585.
68. Wang Y., Dong Q., Zhang Q., Li Z., Wang E., Qiu X. Overexpression of Yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Science 2010.
69. Zhang X., George J., Deb S., Degoutin J.L., Takano E.A., Fox S.B., et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011, 30:2810-2822.
70. Muramatsu T., Imoto I., Matsui T., Kozaki K., Haruki S., Sudol M., et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011, 32:389-398.
71. Xu M.Z., Chan S.W., Liu A.M., Wong K.F., Fan S.T., Chen J., et al. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene 2011, 30:1229-1240.
72. Zhang J., Ji J.Y., Yu M., Overholtzer M., Smolen G.A., Wang R., et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biology 2009, 11:1444-1450.
73. Cao X., Pfaff S.L., Gage F.H. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes and Development 2008, 22:3320-3334.
74. Lian I., Kim J., Okazawa H., Zhao J., Zhao B., Yu J., et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes and Development 2010, 24:1106-1118.
75. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer 2009, 9:265-273.
76. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
77. Richardson A.L., Wang Z.C., De Nicolo A., Lu X., Brown M., Miron A., et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006, 9:121-132.
78. Han W., Jung E.M., Cho J., Lee J.W., Hwang K.T., Yang S.J., et al. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes, Chromosomes & Cancer 2008, 47:490-499.
79. Lai D., Ho K.C., Hao Y., Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Research 2011, 71:2728-2738.
80. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147:759-772.
81. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
82. Zhou Z., Hao Y., Liu N., Raptis L., Tsao M.S., Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 2011, 30:2181-2186.
83. Bhat K.P., Salazar K.L., Balasubramaniyan V., Wani K., Heathcock L., Hollingsworth F., et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes and Development 2011, 25:2594-2609.